Combination treatment for advanced head and neck cancer
Part of Cancer clinical trials.
This study tests a combination of two medications—cetuximab (a targeted antibody) and either pembrolizumab or finotonlimab (immunotherapies)—along with chemotherapy, for advanced head and neck cancer that has spread or come back. The goal is to see if this combination helps shrink tumors and improve survival compared to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You need to have a type of head and neck cancer called squamous cell carcinoma that has spread or come back and can’t be cured by surgery or radiation.
- Your cancer must have either spread to other parts of the body, or—if it’s only in the same area—you must have already had radiation therapy.
- You cannot have had chemotherapy for your current cancer before. If you had chemo in the past as part of your main treatment, it must have ended more than 6 months ago.
- You must be in generally good health, with limited everyday activity limitations (ECOG 0 or 1).
- You must have at least one tumor that can be measured on a CT or MRI scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests three drugs (finotonlimab, cetuximab, and docetaxel) given before surgery to remove recurrent head and neck cancer in patients whose cancer stopped responding to previous immunotherapy. The goal is to shrink the tumor and improve surgical outcomes.
This trial studies penpulimab (an immune medicine) combined with cetuximab (an antibody drug) for recurrent or metastatic squamous cell head and neck cancer that cannot be treated with surgery or radiation. It aims to shrink tumors and improve survival in people whose tumor shows a specific immune marker (PD-L1).
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus a targeted therapy (cetuximab) for people with advanced head and neck cancer that has gotten worse after treatment with pembrolizumab (with or without initial chemotherapy). The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial tests whether adding cetuximab to the standard drug pembrolizumab works better for head and neck cancer that has spread or come back after treatment. It is for people whose cancer did not respond to platinum chemotherapy and whose tumors have a certain immune marker (PD-L1).
This trial tests a combination of three immunotherapy drugs (PD-L1 t-haNK, NAI IL-15sa, and cetuximab) for people with head and neck squamous cell carcinoma that has spread or cannot be cured. The goal is to see if this treatment can shrink tumors or slow the disease.
This trial tests a combination of three drugs (cetuximab, tislelizumab, and chemotherapy) in people with advanced head and neck cancer that hasn't been treated before. The goal is to see if this mix can shrink tumors and improve outcomes.
Hear when a new Squamous Cell Carcinoma of Head and Neck trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.